Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

Eligibility Criteria

• 1. Patients who have chosen to start ocrelizumab and for whom ocrelizumab is determined to be the most appropriate standard-of-care disease modifying therapy (DMT) by the treating neurologist.
• 2. May be treatment naive, or had suboptimal response to no more than one DMT after an adequate course of treatment (defined as treatment duration of 6+ months).
• 3. Age 18 to 60 years old.
• 4. Ethnicity: self-identified as African American or Caucasian.
• 5. Clinically definite relapsing remitting multiple sclerosis (RRMS) per 2017 revised McDonald criteria.
• 6. EDSS from 0 to 6 (inclusive) at baseline visit.
• 7. Able to give informed consent.
• 8. Able to have MRI scans.
• 1. Treatment with another monoclonal antibody, including but not limited to natalizumab, alemtuzumab, daclizumab.
• 2. Failed 2 or more DMTs.
• 3. Treatment with immunosuppressant agents, such as chemotherapeutic agents.
• 4. Claustrophobia.
• 5. Allergy to contrast.
• 6. Significant medical problems that the PI determines will interfere with the conduct of the study.
• 7. Relapse or use of corticosteroids within 30 days prior to baseline visit.
• 8. Pregnancy.
• 9. History of kidney or liver insufficiency.
• 10. History of malignancy.